Retrogenix

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. See our advice if the article is about you and read our scam warning in case someone asks for money to edit this article. (January 2022) (Learn how and when to remove this message) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. See our advice if the article is about you and read our scam warning in case someone asks for money to edit this article. (January 2022) (Learn how and when to remove this message) (Learn how and when to remove this message)

Retrogenix is a biotechnology company based in the United Kingdom. Founded by Jim Freeth and Jo Soden in 2008, the company was acquired in April 2021 by Charles River Laboratories and is now known as the ‘High Peak’ site.

Research and development

Currently, more than 4,500 proteins are simultaneously expressed in the Cell Microarray system for individual screening. The human expression system allows for correct folding and localisation at the surface of the cell and there are documented cases of biological interactions that are mediated by post-translational modifications being detected using the technology.

Applications in medical research

The Cell Microarray technology identifies targets and receptors that are important in the understanding of normal biological and disease processes. Diverse ligands can be screened using the technology which has led to the discovery of key receptors for malaria proteins and targets that mediate virus binding to human cells.

Target deconvolution

Cell Microarray screening identifies the receptors for biologic molecules that have been selected through phenotypic screening. Notably, in studies led by Medimmune, the technology identified disease-relevant cell surface antigens of promising phenotypic molecules.

Off-target profiling

Cell Microarray off-target profiling assesses the specificity of ligands, either prior to clinical testing or to uncover the mechanism of action for an observed adverse event or an unexpected pharmacokinetic profile.

Awards

Retrogenix has twice won the Queen's Awards for Enterprise. The first award was granted for innovation in 2015. This was followed by an award for international trade in 2017.

References

External links

• Official website